Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Acute Myeloid Leukemia: Clinical Spectrum of 125 Patients

  • Sultan, Sadia (Department of Hematology & Blood Bank, Liaquat National Hospital and Medical College) ;
  • Zaheer, Hasan Abbas (Pakistan Institute of Medical Sciences) ;
  • Irfan, Syed Mohammed (Department of Hematology & Blood Bank, Liaquat National Hospital and Medical College) ;
  • Ashar, Sana (Department of Hematology & Blood Bank, Liaquat National Hospital and Medical College)
  • Published : 2016.02.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Acute myeloid leukemia is an acquired clonal heterogeneous stem cell disorder. Hence, various parameters are sought out to categorize this disease into subtypes, so that as a consequence specific treatment modalities can be offered. Conventionally, the practically used method for classification utilizes French American British (FAB) criteria based on morphology and cytochemistry. The aim of present study was to determine the current spectrum of AML sub types in patients in Karachi. Materials and Methods: This single centre cross sectional study was conducted at Liaquat National Hospital, Karachi, extending from January 2010 to December 2014. Data were retrieved from archives were analyzed with SPSS version 22. Results: A total of 125 patients were diagnosed at our institution with de novo AML during five years period, 76 males and 49 females. Median age was 34.5 years. AML-M1 was the predominant FAB subtype (23.2%) followed by M2 (18.4%), M3 and M4 (16% each), M0 (14.4%), M5 (7.2%), M6 (3.2%) and M7 (1.6%). Conclusions: AML in Pakistani patients is seen in a relatively young population. The most common FAB subtype observed in our study was acute myeloblastic leukemia, without maturation (M1).

Keywords

References

  1. Ali A, Siddique MK, Shakoori AR (2013). Frequency of NPM1 mutations in pakistani acute myeloid leukemia patients. Pakistan J Zool, 45, 833-41.
  2. Ahmad F, Mohota R, Sanap S, et al (2014). Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients. Asian Pac J Cancer Prev, 15, 1247-53. https://doi.org/10.7314/APJCP.2014.15.3.1247
  3. Asif N, Hassan K (2013). Acute myeloid leukemia amongst adults. Journal of Islamabad Medical & Dental College, 2, 58-63.
  4. Bennett JM, Catovsky D, Daniel MT, et al (1985). Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med, 103, 620-5. https://doi.org/10.7326/0003-4819-103-4-620
  5. Chaudhry MT, Tayyab M, Faooqi IA (1993). Acute nonlymphoblastic leukemia in adults. J Pak Med Assoc, 43, 259-61.
  6. Gregory T, Wald D, Chen Y (2009). Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. Journal of Hematology & Oncology, 2, 23. https://doi.org/10.1186/1756-8722-2-23
  7. Hassan K, Qureshi M, Shafi S, et al (1993). Acute myeloid leukaemia- FAB classification and its correlation with clinico- heamatological features. J Pak Med Assoc, 43, 200-3.
  8. Harani MS, Adil SN, Shaikh MU, et al (2005). Frequency of fab subtypes in acute myeloid leukemia patients at Aga Khan University Hospital Karachi. J Ayub Med Coll Abbottabad, 17, 26-9.
  9. Hamayun M, Khan SA, Muhammad W (2005). Investigation on the prevalence of leukemia in north west frontier province of Pakistan. Turkish journal of cancer, 35, 119-22.
  10. Harakati MS, Al-Momen AM, Ajarim DS, et al (1998). Adult acute myeloblastic leukemia: Experience at King Khalid University Hospital. Ann Saudi Med, 18, 221-5. https://doi.org/10.5144/0256-4947.1998.221
  11. Juliusson G, Antunovic P, Derolf A, et al (2009). Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood, 113, 4179-87. https://doi.org/10.1182/blood-2008-07-172007
  12. Kakepoto GN, Burney IA, Zaki S, et al (2002). Long-term outcomes of acute myeloid leukemia in adults in Pakistan. J Pak Med Assoc, 52, 482-6.
  13. Lazarevic V, Horstedt AS, Johansson B, et al (2014). Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer J, 28, 188.
  14. Mawali A, Gillis D, Lewis L (2013). Characteristics and Prognosis of Adult Acute Myeloid Leukemia with Internal Tandem Duplication in the FLT3 Gene. Oman Med J, 28, 432-40. https://doi.org/10.5001/omj.2013.121
  15. McKenna RW (2000). Multifaceted approach to the diagnosis and classification of acute leukemias. Clin Chem, 46, 1252-9.
  16. Nakase K, Bradstock K, Sartor M, et al (2000). Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: a comparative study of Australian and Japanese adult cases. Leukemia, 14, 163-8. https://doi.org/10.1038/sj.leu.2401638
  17. Ossenkoppele G, Lowenberg B (2015). How I treat the older patient with acute myeloid leukemia. Blood, 125, 767-74. https://doi.org/10.1182/blood-2014-08-551499
  18. Pastore F, Dufour A, Benthaus T, et al (2014). Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol, 20, 1586-94.
  19. Sarojam S, Vijay S, Raveendran S (2014). FLT3 Mutation as a Significant Prognostic Marker in de novo Acute myeloid leukemia patients: Incidence, distribution and association of cytogenetics findings in South India. Middle East Journal Cancer, 5, 185-96.
  20. Schlenk RF (2014). Post-remission therapy for acute myeloid leukemia. Haematologica, 99, 1663-70. https://doi.org/10.3324/haematol.2014.114611
  21. Schoch C, Haferlach T (2002). Cytogenetics in acute myeloid leukemia. Curr Oncol Rep, 4, 390-7. https://doi.org/10.1007/s11912-002-0032-0
  22. Spence DG, Roberts GT, De Vol EB, et al (1988). Acute myeloid leukemia in Saudia Arabia: Morphologic classification using FAB subgroups. Ann Saudi Med, 8, 179-84. https://doi.org/10.5144/0256-4947.1988.179
  23. Su L, Li X, Gao SJ, et al (2014). Cytogenetic and genetic mutation features of de novo acute myeloid leukemia in elderly Chinese patients. Asian Pac J Cancer Prev, 15, 895-8. https://doi.org/10.7314/APJCP.2014.15.2.895
  24. Tien HF, Wang CH, Lin MT, et al (1995). Correlation of cytogenetic results with immunophenotype, genotype, chemical features and ras mutation in acute myeloid leukemia: a study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet, 84, 60-8. https://doi.org/10.1016/0165-4608(95)00084-4
  25. Walter RB, Othus M, Burnett AK, et al (2013). Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood, 121, 2424-31. https://doi.org/10.1182/blood-2012-10-462440
  26. Yang XF, Sun AN, Yin J, et al (2012). Monosomal karyotypes among 1147 Chinese patients with acute myeloid leukemia: prevalence, features and prognostic impact. Asian Pac J Cancer Prev, 13, 5421-6. https://doi.org/10.7314/APJCP.2012.13.11.5421
  27. Zhou L, Zhu YY, Zhang XD, et al (2013). Risk effects of GST gene polymorphisms in patients with acute myeloid leukemia: a prospective study. Asian Pac J Cancer Prev, 14, 3861-4. https://doi.org/10.7314/APJCP.2013.14.6.3861